ReviewFrontiers in endocrinology2014
The emerging role of insulin and insulin-like growth factor signaling in cancer stem cells.
Review in Frontiers in endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 142 citations in OpenAlex.
- The integrated theory of carcinogenesis: cancer as dysregulated persistence under chronic systemic stress.Frontiers in oncology · 2026Article
- Associations of Stem Cell Markers with Lobular Involution in Benign Breast Tissue.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Associations of circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 with the expression of stem cell markers in benign breast tissue.Breast cancer research : BCR · 2025Article
- Dietary patterns and hepatocellular carcinoma risk: a systematic review and meta-analysis of cohort and case-control studies.Nutrition & metabolism · 2024Review
- Diet, lifestyle factors, comorbidities, and hepatocellular carcinoma risk in a middle eastern country: a case-control study.BMC cancer · 2024Article
- Diverse roles of UBE2S in cancer and therapy resistance: Biological functions and mechanisms.Heliyon · 2024Review
- Obesity and cancer stem cells: Roles in cancer initiation, progression and therapy resistance.World journal of stem cells · 2023Review
- Metabolic risk factors of ovarian cancer: a review.JBRA assisted reproduction · 2022Review
- Hallmarks of cancer: The insulin-like growth factors perspective.Frontiers in oncology · 2022Review
- Lipid raft involvement in signal transduction in cancer cell survival, cell death and metastasis.Cell proliferation · 2022Review
- UBE2S activates NF-κB signaling by binding with IκBα and promotes metastasis of lung adenocarcinoma cells.Cellular oncology (Dordrecht, Netherlands) · 2021Article
- Pongol Methyl Ether Inhibits Akt and Suppresses Cancer Stem Cell Phenotypes in Lung Cancer Cells.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Adiposity, Adulthood Weight Change, and Risk of Incident Hepatocellular Carcinoma.Cancer prevention research (Philadelphia, Pa.) · 2021Article
- Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3NPJ breast cancer · 2021Article
- Reduced Insulin-Like Growth Factor Family Member Expression Predicts Neurogenesis Marker Expression in the Subependymal Zone in Schizophrenia and Bipolar Disorder.Schizophrenia bulletin · 2021Article
- Review
- ZYG11A Is Expressed in Epithelial Ovarian Cancer and Correlates With Low Grade Disease.Frontiers in endocrinology · 2021Article
- The C-X-C Motif Chemokine Ligand 1 Sustains Breast Cancer Stem Cell Self-Renewal and Promotes Tumor Progression and Immune Escape Programs.Frontiers in cell and developmental biology · 2021Article
- Review
- IGF2 loss of imprinting enhances colorectal cancer stem cells pluripotency by promoting tumor autophagy.Aging · 2020Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer cells frequently exploit the IGF signaling, a fundamental pathway mediating development, cell growth, and survival. As a consequence, several components of the IGF signaling are deregulated in cancer and sustain cancer progression. However, specific targeting of IGF-IR in humans has resulted efficacious only in small subsets of cancers, making researches wondering whether IGF system targeting is still worth pursuing in the clinical setting. Although no definite answer is yet available, it has become increasingly clear that other components of the IGF signaling pathway, such as IR-A, may substitute for the lack of IGF-IR, and induce cancer resistance and/or clonal selection. Moreover, accumulating evidence now indicates that IGF signaling is a central player in the induction/maintenance of epithelial mesenchymal transition (EMT) and cell stemness, two strictly related programs, which play a key role in metastatic spread and resistance to cancer treatments. Here we review the evidences indicating that IGF signaling enhances the expression of transcription factors implicated in the EMT program and has extensive cross-talk with specific pathways involved in cell pluripotency and stemness maintenance. In turn, EMT and cell stemness activate positive feed-back mechanisms causing up-regulation of various IGF signaling components. These findings may have novel translational implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.